France sets up agency for medical bioethics
By Agence France-Presse,
Agence France-Presse
| 05. 10. 2005
PARIS (AFP) - France inaugurated a specialised agency for approving research on embryonic stem cells and vetting organ donations and other bioethics issues.
The creation of the Biomedicine Agency follows up on a new law, approved by parliament last August and due to take effect this month.
Under it, French health scientists will be permitted to draw on the country's stock of tens of thousands of surplus embryos in order to create lines of stem cells.
These embryos were created years ago through in-vitro fertilisation (IVF) to help infertile couples, but are no longer wanted and remain in freezers in fertility clinics.
Stem cells are immature cells that are like blank slates. In this early state, they have yet to differentiate into the specific cells that make up the body's tissues.
The goal among scientists is to harvest these cells and coax them into growing into fresh, replacement tissue which can then be transplanted into the body to reverse brain, nerve, muscle and organ damage.
The most versatile stem cells come from embryos that are a few days old. These...
Related Articles
By Priyanka Runwal, Chemical and Engineering News | 08.05.2024
Saritee Sanodiya, 26, has spent countless days wondering if she’ll ever live a “normal” life. Growing up, Sanodiya often missed school, frequenting the hospital for sudden, life-threatening drops in her hemoglobin levels and excruciating pain in her joints. High fever...
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024